Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human Study of DRP-104 in Advanced Solid Tumors
NCT04471415Phase 2Terminated
- Sponsor
- Dracen Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of sirpiglenastat in solid tumor and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Dracen Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 2 years, Pharmacokinetics at 1 year and 2 more. Started Aug 2020; status: terminated.
02
Drugs
sirpiglenastat
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04471415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471415.